Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Velcade

(Bortezomib Injection)

SShilpa Grover, MD, MPH

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

7

FDA Applications

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04151667·33 enrolled

Regulatory

FDA Approval Timeline[3]

May 13, 2003

VELCADE

NDA NDA021602

Nov 6, 2017

BORTEZOMIB

NDA NDA205004

Oct 4, 2019

BORTEZOMIB

NDA NDA206927

May 2, 2022

BORTEZOMIB

NDA NDA209191

Jul 26, 2022

BORTEZOMIB

NDA NDA215441

Jul 27, 2022

BORTEZOMIB

NDA NDA215331

Aug 26, 2024

BORTEZOMIB

NDA NDA212782

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bortezomib Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bortezomib Injection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA212782). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Shilpa Grover, MD, MPH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: SShilpa Grover, MD, MPH

Related News